See more : Automobile & PCB Inc. (015260.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Covetrus, Inc. (CVET) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Covetrus, Inc., a leading company in the Medical – Distribution industry within the Healthcare sector.
- Knight Club Capital Asset Management Public Company Limited (KCC.BK) Income Statement Analysis – Financial Results
- Kwan On Holdings Limited (1559.HK) Income Statement Analysis – Financial Results
- Goldshore Resources Inc. (GSHR.V) Income Statement Analysis – Financial Results
- Pardes Biosciences, Inc. (PRDS) Income Statement Analysis – Financial Results
- Südzucker AG (SUEZY) Income Statement Analysis – Financial Results
Covetrus, Inc. (CVET)
About Covetrus, Inc.
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions, such as inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software, data-driven applications, client communications tools, and related services to increase staff efficiency and enhance business health; and solutions that integrate with its software platforms, including client communication services, reminders, data backup services, hardware sales and support, and credit card processing services for veterinary practitioners and animal-health clinics. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as offers shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal, equine, and large-animal markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine. As of October 13, 2022, Covetrus, Inc. was taken private.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|
| Revenue | 4.58B | 4.34B | 3.98B | 3.78B | 3.58B | 3.35B | 2.98B |
| Cost of Revenue | 3.72B | 3.54B | 3.23B | 3.09B | 2.93B | 2.73B | 2.45B |
| Gross Profit | 858.00M | 798.00M | 749.00M | 684.11M | 652.03M | 619.91M | 530.02M |
| Gross Profit Ratio | 18.75% | 18.39% | 18.84% | 18.11% | 18.21% | 18.49% | 17.80% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 867.00M | 808.00M | 538.47M | 516.70M | 488.82M | 417.87M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 881.00M | 867.00M | 808.00M | 538.47M | 516.70M | 488.82M | 417.87M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 881.00M | 867.00M | 808.00M | 538.47M | 516.70M | 488.82M | 417.87M |
| Cost & Expenses | 4.60B | 4.41B | 4.04B | 3.63B | 3.44B | 3.22B | 2.87B |
| Interest Income | 0.00 | 1.00M | 7.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 32.00M | 47.00M | 56.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 200.00M | 190.00M | 176.00M | 64.10M | 59.05M | 55.45M | 50.30M |
| EBITDA | 178.00M | 211.00M | -794.00M | 201.99M | 171.43M | 153.68M | 134.89M |
| EBITDA Ratio | 3.89% | 4.86% | -19.97% | 5.35% | 4.79% | 4.58% | 4.53% |
| Operating Income | -22.00M | -69.00M | -997.00M | 137.10M | 135.32M | 123.83M | 103.81M |
| Operating Income Ratio | -0.48% | -1.59% | -25.08% | 3.63% | 3.78% | 3.69% | 3.49% |
| Total Other Income/Expenses | -32.00M | 45.00M | -32.00M | 6.08M | 3.45M | 2.97M | 4.69M |
| Income Before Tax | -54.00M | -24.00M | -1.03B | 143.18M | 138.77M | 126.79M | 108.50M |
| Income Before Tax Ratio | -1.18% | -0.55% | -25.88% | 3.79% | 3.88% | 3.78% | 3.64% |
| Income Tax Expense | 32.00M | -7.00M | -7.00M | 37.03M | 48.02M | 27.94M | 24.27M |
| Net Income | -86.00M | -19.00M | -1.02B | 100.86M | 64.35M | 70.30M | 60.32M |
| Net Income Ratio | -1.88% | -0.44% | -25.63% | 2.67% | 1.80% | 2.10% | 2.03% |
| EPS | -0.63 | -0.16 | -9.52 | 0.91 | 0.58 | 0.63 | 0.54 |
| EPS Diluted | -0.63 | -0.16 | -9.52 | 0.91 | 0.58 | 0.63 | 0.54 |
| Weighted Avg Shares Out | 137.00M | 118.00M | 107.00M | 111.19M | 111.19M | 111.19M | 111.19M |
| Weighted Avg Shares Out (Dil) | 137.00M | 118.00M | 107.00M | 111.19M | 111.19M | 111.19M | 111.19M |
Covetrus (CVET) Matches Q3 Earnings Estimates
Covetrus: Q3 Earnings Insights
Covetrus Announces Third Quarter 2021 Earnings Release Date and Conference Call Information
Covetrus Announces Third Quarter 2021 Earnings Release Date and Conference Call Information
Covetrus, Inc. (CVET) CEO Ben Wolin on Q2 2021 Results - Earnings Call Transcript
Covetrus (CVET) Reports Q2 Loss, Tops Revenue Estimates
Covetrus Announces Second Quarter 2021 Earnings Release Date and Conference Call Information
Covetrus Appoints New Chief Accounting Officer
Overview Of Opportunities In Animal Companionship: A $200B Industry Growing At 6.1% Annually
Covetrus Integrates Prescription and Practice Management Technologies
Source: https://incomestatements.info
Category: Stock Reports